Antibacterial activity of the new quinolone CI-960 (PD 127391) against clinical isolates at a major tertiary care center in Saudi Arabia.
The antibacterial activity of the new fluoroquinolone CI-960 (PD 127391) was evaluated against 1,162 clinical isolates and compared with other quinolones and various commonly used antibiotics. CI-960 was highly effective against members of Enterobacteriaceae inhibiting 626 of the 629 isolates at a less than or equal to 0.03 to 0.12 microgram/ml concentration. All the 305 isolates of Pseudomonas aeruginosa, Xanthomona maltophilia, and Acinetobacter were susceptible to CI-960. It was the only effective drug against 10 multi-resistant isolates of pseudomonads and Acinetobacter. All staphylococci, including methicillin-resistant Staphylococcus aureus, were inhibited by less than or equal to 0.03-0.5 microgram/ml of CI-960. Like other drugs of its class, it had little activity against enterococci.